Proof of concept studies for tissue-protective agents in multiple sclerosis

Lahar R. Mehta, S. R. Schwid, D. L. Arnold, G. R. Cutter, S. Aradhye, L. J. Balcer, Peter Calabresi, J. A. Cohen, P. E. Cole, R. Glanzman, S. Goelz, M. Inglese, R. Kapoor, L. Kappos, R. Kreitman, F. D. Lublin, A. Mann, R. A. Marrie, P. O'Looney, C. H. Polman & 5 others B. M. Ravina, S. C. Reingold, J. R. Richert, A. W. Sandrock, E. Waubant

Research output: Contribution to journalArticle

Abstract

Background: There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives: We convened a group of MS clinical trialists and related researchers to discuss designs for proof of concept studies utilizing currently available data and assessment methods. Results: Our favored design was a randomized, double-blind, parallel-group study of active treatment versus placebo focusing on changes in brain volume from a post-baseline scan (3-6 months after starting treatment) to the final visit 1 year later. Study designs aimed at reducing residual deficits following acute exacerbations are less straightforward, depending greatly on the anticipated rapidity of treatment effect onset. Conclusions: The next step would be to perform one or more studies of potential tissue-protective agents with these designs in mind, creating the longitudinal data necessary to refine endpoint selection, eligibility criteria, and sample size estimates for future trials.

Original languageEnglish (US)
Pages (from-to)542-546
Number of pages5
JournalMultiple Sclerosis
Volume15
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Protective Agents
Multiple Sclerosis
Therapeutics
Sample Size
Patient Selection
Placebos
Research Personnel
Brain

Keywords

  • Clinical trial designs
  • Multiple sclerosis
  • Outcome measurement
  • Tissue protection

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Mehta, L. R., Schwid, S. R., Arnold, D. L., Cutter, G. R., Aradhye, S., Balcer, L. J., ... Waubant, E. (2009). Proof of concept studies for tissue-protective agents in multiple sclerosis. Multiple Sclerosis, 15(5), 542-546. https://doi.org/10.1177/1352458508101939

Proof of concept studies for tissue-protective agents in multiple sclerosis. / Mehta, Lahar R.; Schwid, S. R.; Arnold, D. L.; Cutter, G. R.; Aradhye, S.; Balcer, L. J.; Calabresi, Peter; Cohen, J. A.; Cole, P. E.; Glanzman, R.; Goelz, S.; Inglese, M.; Kapoor, R.; Kappos, L.; Kreitman, R.; Lublin, F. D.; Mann, A.; Marrie, R. A.; O'Looney, P.; Polman, C. H.; Ravina, B. M.; Reingold, S. C.; Richert, J. R.; Sandrock, A. W.; Waubant, E.

In: Multiple Sclerosis, Vol. 15, No. 5, 2009, p. 542-546.

Research output: Contribution to journalArticle

Mehta, LR, Schwid, SR, Arnold, DL, Cutter, GR, Aradhye, S, Balcer, LJ, Calabresi, P, Cohen, JA, Cole, PE, Glanzman, R, Goelz, S, Inglese, M, Kapoor, R, Kappos, L, Kreitman, R, Lublin, FD, Mann, A, Marrie, RA, O'Looney, P, Polman, CH, Ravina, BM, Reingold, SC, Richert, JR, Sandrock, AW & Waubant, E 2009, 'Proof of concept studies for tissue-protective agents in multiple sclerosis', Multiple Sclerosis, vol. 15, no. 5, pp. 542-546. https://doi.org/10.1177/1352458508101939
Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ et al. Proof of concept studies for tissue-protective agents in multiple sclerosis. Multiple Sclerosis. 2009;15(5):542-546. https://doi.org/10.1177/1352458508101939
Mehta, Lahar R. ; Schwid, S. R. ; Arnold, D. L. ; Cutter, G. R. ; Aradhye, S. ; Balcer, L. J. ; Calabresi, Peter ; Cohen, J. A. ; Cole, P. E. ; Glanzman, R. ; Goelz, S. ; Inglese, M. ; Kapoor, R. ; Kappos, L. ; Kreitman, R. ; Lublin, F. D. ; Mann, A. ; Marrie, R. A. ; O'Looney, P. ; Polman, C. H. ; Ravina, B. M. ; Reingold, S. C. ; Richert, J. R. ; Sandrock, A. W. ; Waubant, E. / Proof of concept studies for tissue-protective agents in multiple sclerosis. In: Multiple Sclerosis. 2009 ; Vol. 15, No. 5. pp. 542-546.
@article{ce56fc11f8ae46b48efed1aa82b4baca,
title = "Proof of concept studies for tissue-protective agents in multiple sclerosis",
abstract = "Background: There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives: We convened a group of MS clinical trialists and related researchers to discuss designs for proof of concept studies utilizing currently available data and assessment methods. Results: Our favored design was a randomized, double-blind, parallel-group study of active treatment versus placebo focusing on changes in brain volume from a post-baseline scan (3-6 months after starting treatment) to the final visit 1 year later. Study designs aimed at reducing residual deficits following acute exacerbations are less straightforward, depending greatly on the anticipated rapidity of treatment effect onset. Conclusions: The next step would be to perform one or more studies of potential tissue-protective agents with these designs in mind, creating the longitudinal data necessary to refine endpoint selection, eligibility criteria, and sample size estimates for future trials.",
keywords = "Clinical trial designs, Multiple sclerosis, Outcome measurement, Tissue protection",
author = "Mehta, {Lahar R.} and Schwid, {S. R.} and Arnold, {D. L.} and Cutter, {G. R.} and S. Aradhye and Balcer, {L. J.} and Peter Calabresi and Cohen, {J. A.} and Cole, {P. E.} and R. Glanzman and S. Goelz and M. Inglese and R. Kapoor and L. Kappos and R. Kreitman and Lublin, {F. D.} and A. Mann and Marrie, {R. A.} and P. O'Looney and Polman, {C. H.} and Ravina, {B. M.} and Reingold, {S. C.} and Richert, {J. R.} and Sandrock, {A. W.} and E. Waubant",
year = "2009",
doi = "10.1177/1352458508101939",
language = "English (US)",
volume = "15",
pages = "542--546",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Proof of concept studies for tissue-protective agents in multiple sclerosis

AU - Mehta, Lahar R.

AU - Schwid, S. R.

AU - Arnold, D. L.

AU - Cutter, G. R.

AU - Aradhye, S.

AU - Balcer, L. J.

AU - Calabresi, Peter

AU - Cohen, J. A.

AU - Cole, P. E.

AU - Glanzman, R.

AU - Goelz, S.

AU - Inglese, M.

AU - Kapoor, R.

AU - Kappos, L.

AU - Kreitman, R.

AU - Lublin, F. D.

AU - Mann, A.

AU - Marrie, R. A.

AU - O'Looney, P.

AU - Polman, C. H.

AU - Ravina, B. M.

AU - Reingold, S. C.

AU - Richert, J. R.

AU - Sandrock, A. W.

AU - Waubant, E.

PY - 2009

Y1 - 2009

N2 - Background: There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives: We convened a group of MS clinical trialists and related researchers to discuss designs for proof of concept studies utilizing currently available data and assessment methods. Results: Our favored design was a randomized, double-blind, parallel-group study of active treatment versus placebo focusing on changes in brain volume from a post-baseline scan (3-6 months after starting treatment) to the final visit 1 year later. Study designs aimed at reducing residual deficits following acute exacerbations are less straightforward, depending greatly on the anticipated rapidity of treatment effect onset. Conclusions: The next step would be to perform one or more studies of potential tissue-protective agents with these designs in mind, creating the longitudinal data necessary to refine endpoint selection, eligibility criteria, and sample size estimates for future trials.

AB - Background: There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives: We convened a group of MS clinical trialists and related researchers to discuss designs for proof of concept studies utilizing currently available data and assessment methods. Results: Our favored design was a randomized, double-blind, parallel-group study of active treatment versus placebo focusing on changes in brain volume from a post-baseline scan (3-6 months after starting treatment) to the final visit 1 year later. Study designs aimed at reducing residual deficits following acute exacerbations are less straightforward, depending greatly on the anticipated rapidity of treatment effect onset. Conclusions: The next step would be to perform one or more studies of potential tissue-protective agents with these designs in mind, creating the longitudinal data necessary to refine endpoint selection, eligibility criteria, and sample size estimates for future trials.

KW - Clinical trial designs

KW - Multiple sclerosis

KW - Outcome measurement

KW - Tissue protection

UR - http://www.scopus.com/inward/record.url?scp=65349186498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349186498&partnerID=8YFLogxK

U2 - 10.1177/1352458508101939

DO - 10.1177/1352458508101939

M3 - Article

VL - 15

SP - 542

EP - 546

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 5

ER -